XML 73 R62.htm IDEA: XBRL DOCUMENT v3.25.1
Debt - Liability for Sale of Future Royalties (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2025
USD ($)
Debt Disclosure [Abstract]  
Beginning balance $ 2,081,776
Less: Non-cash royalty revenue payable to Royalty Pharma (32,974)
Plus: non-cash interest expense recognized 49,661
Ending balance $ 2,098,463
Effective interest rate of the liability component 9.30%